© 2020 MJH Life Sciences and HCPLive. All rights reserved.
August 05, 2020
Older, white patients and those who use linagliptin are at a higher risk of bullous pemphigoid.
July 31, 2020
The FDA will be working over the next few months to ensure tralokinumab is efficient for atopic dermatitis.
An expert explains differences between tralokinumab and other popular agents for atopic dermatitis.
The expansion makes history for the injection biologic.
July 24, 2020
Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.
Kim Kjøller, MD, discusses how tralokinumab can be used for the treatment of atopic dermatitis.
July 21, 2020
Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.
July 16, 2020
Of the 21 patients included in the study with COVID-19 and skin rash, 29% had enanthem.
July 15, 2020
Although a majority of pediatricians are aware of the guidelines, less than one-third of survey respondents report full implementation.
July 14, 2020
Guselkumab represents the first FDA approved medication for active psoriatic arthritis that selectively inhibits interleukin-23.